Table 4.
Multivariable Analyses of Differences in the eGFR Slope and Risk of the Composite Renal Outcome in the CRIC Study.*
| Multivariate Model and Comparison Group | Difference in eGFR Slope | Risk of Composite Renal Outcome | ||||||
|---|---|---|---|---|---|---|---|---|
| With Diabetes | Without Diabetes | With Diabetes | Without Diabetes | |||||
| ml/min/1.73 m2/yr (95% CI) | P value | ml/min/1.73 m2/yr (95% CI) | P value | hazard ratio (95% CI) | P value | hazard ratio (95% CI) | P value | |
| Model 1 | ||||||||
|
| ||||||||
| All black patients vs. all white patients | −1.08 (−1.48 to −0.69) | <0.001 | −0.28 (−0.57 to 0.01) | 0.06 | 1.77 (1.42 to 2.20) | <0.001 | 2.20 (1.65 to 2.94) | <0.001 |
|
| ||||||||
| Black patients with APOL1 high risk vs. all white patients | −2.00 (−2.72 to −1.28) | <0.001 | −1.12 (−1.6 to −0.63) | <0.001 | 2.48 (1.79 to 3.43) | <0.001 | 3.05 (2.07 to 4.48) | <0.001 |
|
| ||||||||
| Black patients with APOL1 low risk vs. all white patients | −0.92 (−1.33 to −0.52) | <0.001 | −0.05 (−0.36 to 0.25) | 0.72 | 1.65 (1.32 to 2.07) | <0.001 | 1.96 (1.44 to 2.67) | <0.001 |
|
| ||||||||
| Model 2 | ||||||||
|
| ||||||||
| All black patients vs. all white patients | −0.96 (−1.37 to −0.55) | <0.001 | −0.28 (−0.59 to 0.03) | 0.07 | 1.79 (1.43 to 2.24) | <0.001 | 2.15 (1.58 to 2.91) | <0.001 |
|
| ||||||||
| Black patients with APOL1 high risk vs. all white patients | −1.95 (−2.68 to −1.22) | <0.001 | −1.16 (−1.66 to −0.66) | <0.001 | 2.48 (1.78 to 3.45) | <0.001 | 3.05 (2.05 to 4.53) | <0.001 |
|
| ||||||||
| Black patients with APOL1 low risk vs. all white patients | −0.78 (−1.20 to −0.36) | <0.001 | −0.04 (−0.36 to 0.29) | 0.82 | 1.67 (1.32 to 2.11) | <0.001 | 1.88 (1.36 to 2.61) | <0.001 |
|
| ||||||||
| Model 3 | ||||||||
|
| ||||||||
| All black patients vs. all white patients | −0.48 (−0.88 to −0.09) | 0.02 | −0.17 (−0.48 to 0.13) | 0.27 | 1.49 (1.18 to 1.88) | <0.001 | 1.80 (1.31 to 2.49) | <0.001 |
|
| ||||||||
| Black patients with APOL1 high risk vs. all white patients | −1.32 (−2.02 to −0.63) | <0.001 | −1.05 (−1.54 to −0.56) | <0.001 | 1.95 (1.39 to 2.73) | <0.001 | 2.68 (1.78 to 4.05) | <0.001 |
|
| ||||||||
| Black patients with APOL1 low risk vs. all white patients | −0.35 (−0.75 to 0.06) | 0.09 | 0.08 (−0.25 to −0.40) | 0.65 | 1.40 (1.10 to 1.78) | 0.006 | 1.57 (1.11 to 2.21) | 0.01 |
|
| ||||||||
| Model 4 | ||||||||
|
| ||||||||
| All black patients vs. all white patients | −0.21 (−0.55 to 0.14) | 0.25 | −0.21 (−0.50 to 0.08) | 0.16 | 1.34 (1.06 to 1.70) | 0.02 | 1.98 (1.44 to 2.72) | <0.001 |
|
| ||||||||
| Black patients with APOL1 high risk vs. all white patients | −0.79 (−1.41 to −0.17) | 0.01 | −0.81 (−1.26 to −0.35) | <0.001 | 1.58 (1.12 to 2.24) | 0.009 | 2.84 (1.84 to 4.38) | <0.001 |
|
| ||||||||
| Black patients with APOL1 low risk vs. all white patients | −0.11 (−0.47 to 0.25) | 0.55 | −0.03 (−0.34 to 0.27) | 0.84 | 1.29 (1.01 to 1.65) | 0.04 | 1.78 (1.28 to 2.49) | <0.001 |
The composite outcome was incident end-stage renal disease or a reduction of 50% in the eGFR from baseline. The APOL1 risk was based on the recessive genetic model. Model 1 is the multivariable-adjusted base model with adjustment for age, sex, clinical site, and baseline eGFR. Model 2 includes all the variables in model 1 plus education level, treatment by a nephrologist, and the use of either an angiotensin-converting–enzyme inhibitor or an angiotensin-receptor blocker. Model 3 includes all the variables in model 2 plus systolic blood pressure, body-mass index, glycated hemoglobin level, and smoking status. Model 4 includes all the variables in model 3 plus the total 24-hour urinary protein excretion.